Vegh Z - Search Results

1

Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.

Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, Lakatos PL. Gulacsi L, et al. Among authors: vegh z. Curr Med Chem. 2019;26(2):259-269. doi: 10.2174/0929867324666170406112304. Curr Med Chem. 2019. PMID: 28393687 Review.

2

Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.

Vegh Z, Kurti Z, Lakatos PL. Vegh Z, et al. Dig Dis. 2017;35(1-2):101-106. doi: 10.1159/000449089. Epub 2017 Feb 1. Dig Dis. 2017. PMID: 28147369 Review.

3

New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe.

Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. Lovasz BD, et al. Among authors: vegh z. Dig Liver Dis. 2013 Apr;45(4):269-76. doi: 10.1016/j.dld.2012.08.020. Epub 2012 Sep 24. Dig Liver Dis. 2013. PMID: 23010518 Review.

4

Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort.

Vegh Z, Golovics PA, Lovasz BD, Kurti Z, Gecse KB, Szita I, Balogh M, Pandur T, Lakatos L, Lakatos PL. Vegh Z, et al. Scand J Gastroenterol. 2015 Mar;50(3):306-11. doi: 10.3109/00365521.2014.985708. Epub 2014 Dec 4. Scand J Gastroenterol. 2015. PMID: 25471148

5

Optimizing biological therapy in Crohn's disease.

Gecse KB, Végh Z, Lakatos PL. Gecse KB, et al. Among authors: vegh z. Expert Rev Gastroenterol Hepatol. 2016;10(1):37-45. doi: 10.1586/17474124.2016.1096198. Epub 2015 Oct 16. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26471077 Review.

6

'Treat to Target' - Lessons Learnt.

Kurti Z, Vegh Z, Golovics PA, Lakatos PL. Kurti Z, et al. Among authors: vegh z. Dig Dis. 2016;34(1-2):147-52. doi: 10.1159/000443131. Epub 2016 Mar 16. Dig Dis. 2016. PMID: 26981855 Review.

7

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T. Farkas K, et al. Among authors: vegh z. J Crohns Colitis. 2016 Nov;10(11):1273-1278. doi: 10.1093/ecco-jcc/jjw085. Epub 2016 Apr 21. J Crohns Colitis. 2016. PMID: 27106537 Clinical Trial.

8

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.

Kurti Z, Vegh Z, Golovics PA, Fadgyas-Freyler P, Gecse KB, Gonczi L, Gimesi-Orszagh J, Lovasz BD, Lakatos PL. Kurti Z, et al. Among authors: vegh z. Dig Liver Dis. 2016 Nov;48(11):1302-1307. doi: 10.1016/j.dld.2016.07.012. Epub 2016 Jul 21. Dig Liver Dis. 2016. PMID: 27481587

9

Epidemiology of inflammatory bowel diseases from west to east.

Vegh Z, Kurti Z, Lakatos PL. Vegh Z, et al. J Dig Dis. 2017 Feb;18(2):92-98. doi: 10.1111/1751-2980.12449. J Dig Dis. 2017. PMID: 28102560 Review.

10

Can we Predict Disease Course with Clinical Factors?

Vegh Z, Kurti Z, Golovics PA, Lakatos PL. Vegh Z, et al. Curr Drug Targets. 2018;19(7):791-797. doi: 10.2174/1389450118666170329095123. Curr Drug Targets. 2018. PMID: 28378692 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page